Combined oral corticosteroid-methotrexate therapy in Eales' disease.
The efficacy of combined oral corticosteroid and low-dose oral methotrexate pulsed therapy in Eales' disease was evaluated prospectively, based on weighted visual morbidity scale for disease activity and visual acuity grading in 36 consecutive cases. Oral corticosteroids in a weekly tapering dose for 4 weeks and 12.5 mg methotrexate as a single oral dose, once per week for 12 weeks, were administered simultaneously. We concluded that this combined oral therapy is clinically effective with an acceptable safety profile.
Saxena
Sandeep
S
Department of Ophthalmology, CSM Medical University, (Erstwhile King George's Medical University), Lucknow. India. sandeepsaxena2020@yahoo.com
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D010689:Phlebitis / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies; D012164:Retinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014792:Visual Acuity; D055815:Young Adult
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D008727:Methotrexate